Press Releases

Date Title and Summary Additional Formats
Toggle Summary SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
Data shows synergistic activity and improved outcomes of SCY-078 in combination with isavuconazole Phase 2 trial in invasive aspergillosis expected to initiate in the third quarter of 2018 JERSEY CITY, N.J. , Feb. 1, 2018 /PRNewswire/ --  SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS to Participate in the Cantor Antibiotics Summit
JERSEY CITY, N.J. , Jan. 11, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in a panel entitled "Novel Ways to
View HTML
Toggle Summary SCYNEXIS Provides Corporate and SCY-078 Pipeline Update
Path Forward Established for IV Program of SCY-078, with Clinical Trials to Initiate in the Third Quarter of 2018 with an Improved IV Formulation Clinical Development of Oral Formulation of SCY-078 Continues to Progress as Planned in Multiple Indications Approvable with an Oral Agent 2018 Strategy
View HTML
Toggle Summary SCYNEXIS to Participate in Upcoming Investor Conferences
JERSEY CITY, N.J. , Nov. 28, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will participate in the following upcoming investor
View HTML
Toggle Summary SCYNEXIS to Present at the 29th Annual Piper Jaffray Healthcare Conference
JERSEY CITY, N.J. , Nov. 22, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 29th Annual Piper Jaffray
View HTML
Toggle Summary SCYNEXIS Appoints Scott Sukenick as General Counsel
- Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) - JERSEY CITY, N.J. , Nov. 16, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced the
View HTML
Toggle Summary SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update
Ongoing Dosing of Patients in Clinical Studies for Two Indications New Data Publications Support the Potential Use of SCY-078 in Multiple New Indications JERSEY CITY, N.J. , Nov. 7, 2017 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative anti-infective
View HTML
Toggle Summary SCYNEXIS Presents New Data Further Supporting SCY-078 as a Potential Treatment for Aspergillus and Candida Infections at IDWeek 2017
In vivo and in vitro data show SCY-078’s favorable profile and potential therapeutic benefit JERSEY CITY, N.J. , Oct. 05, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening
View HTML
Toggle Summary SCYNEXIS to Present Data on Lead Antifungal Candidate SCY-078 at IDWeek 2017
Additional SCY-078 Posters to be Presented at 8 th Trends in Medical Mycology Pre-clinical data further highlight SCY-078’s broad spectrum of activity and differentiated attributes JERSEY CITY, N.J. , Sept. 27, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc.
View HTML
Toggle Summary SCYNEXIS to Present at Upcoming Investor Conferences
JERSEY CITY, N.J., Aug. 31, 2017 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative anti-infective therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor
View HTML